China, Globalisation and Health Biotechnology Innovation: Venture Capital and the Adaptive State
Tóm tắt
This paper explores the changing approach of the Chinese state to health biotechnology innovation and, in particular, the position of venture capital within that process. How has the Chinese state dealt with the opportunities and threats posed by globalisation in this field, what status has it attached to the role of venture capital in innovation and what are the implications of these actions for the role of the state? In addressing these questions, the paper begins by examining the global context of the venture capital and innovation relationship, the varied nature of VC organisation, the business models that inform the VC approach to health biotechnology innovation and the implications of these factors for the role of the state. Secondly, it explores the nature and impact of state intervention in China on the VC contribution to innovation, the particular character of the Chinese VC industry and its economic environment and the capacity of the VC sector to contribute to China’s position as a global player in health technology innovation. The paper concludes by reviewing the insights this case study provides into the problematic character of state adaptation in China to the challenges of globalisation.
Tài liệu tham khảo
Ahlstrom, D., Bruton, G. D., & Kuang, S. Y. (2007). Venture capital in China: Past, present and future. Asia Pacific Journal of Management, 24, 247–68.
Amsden, A. (1989). Asia’s next giant. South Korea and late industrialisation. New York: Oxford University Press.
Andrews, L., & Nelkin, D. (2001). Body Bazaar: The market for human tissue in the biotechnology age. London: Crown.
Applebaum, R. P., & Henderson, J. (eds). (1992). States and development in the Asian Pacific Rim. Newbury Park: Sage.
Balfour, F. (2006). Venture capital’s new promised land. Business Week, 3967, 44.
Black, B., & Gilson, S. (1998). Venture capital and the structure of capital markets: Banks versus stock markets. Journal of Financial Economics, 47, 243–277.
Bruton, G. D., Fried, V. H., & Manigart, S. (2005). Institutional influences on the worldwide expansion of venture capital. Entrepreneurship Theory and Practice, 29(6), 737–60.
ChinaBio Today. (2008). Spotlight on China biomedical investment. Available at: http://seekingalpha.com/article/85836-spotlight-on-china-biomedical-investment Accessed 1st December 2008.
China.org.cn. (2006a). Hu outlines strategic tasks for S and T innovation. Available at: http://english.gov.cn/2006-01/10/content_153815.htm Accessed 6 October 2008.
China.org.cn. (2006b). 11th Five Year Development Guidelines. Available at: http://www.china.org.cn/english/MATERIAL/157595.htm Accessed 7 October 2008.
Doring, O. (2004). Chinese researchers promote biomedical regulations: What the motives of the biopolitical dawn in China and where are they heading? Kennedy Institute of Ethics Journal, 14(1), 39–46.
Edquist, C., & Hommen, L. (eds). (2008). Small country innovation systems. London: Edward Elgar Publishing.
Ernst and Young. (2007). Acceleration. Global venture capital insights report 2007. London: Ernst and Young.
Frew, S., Sammut, S., Shore, A., Ramjist, J., Al-Bader, S., Rezaie, R., et al. (2008). Chinese health biotech and the billion-patient market. Nature Biotechnology, 26(1), 37–53.
Fung, H., Liu, Q., & Shen, M. (2005). Venture capital cycle, opportunities and challenges in China. The Chinese Economy, 37(4), 28–49.
HG.org. (2006). China: venture capital regulations. Available at: http://www.hg.org/articles/article_1193.html Accessed 28th November 2008.
Huang, C., Amorim, C., Spinoglio, M., Gouveia, B., & Medina, A. (2004). Organisation, programme and structure: An analysis of the Chinese innovation policy framework. R and D Management, 34(4), 375–85.
Jia, H., Jayarama, K. S., & Astvatsatuyan, M. (2006). Lack of private financing hobbles emerging biotech regions. Nature Biotechnology, 24(1), 7–9.
Kenney, M. (2009). Venture capital in China and India – a comparison. Corporate Affiliate News. Stanford University. Available at: http://aparcfellows.stanford.edu/news/march_2009_dispatch__venture_capital_in_china_and_india__a_comparison_20090309/ Accessed 23 June 2009.
Kenney, M., Han, K., & Tanaka, S. (2002). Scattering geese: venture capital industries in East Asia. Report to the World Bank. Available at: http://repositories.cdlib.org/cgi/viewcontent.cgi?article=1009&context=brie Accessed 13 November 2008.
Kim, Y. T. (1999). Neoliberalism and the decline of the developmental state. Journal of Contemporary Asia, 29(4), 441–62.
Lord Sainsbury of Turville. (2007). The race to the top. A review of Government’s science and innovation policies. London: HM Treasury.
Mann, M. (1997). Has globalisation ended the rise and rise of the nation state? Review of International Political Economy, 4(3), 472–96.
May, C., & Sell, S. (2005). Intellectual property rights: A critical history. Boulder: Lynnee Rieener.
Ministry of Science and Technology of the People’s Republic of China. (2001). Implementing regulations of the patent law of the People’s Republic of China. Available at: http://www.most.gov.cn/eng/policies/regulations/200501/t20050107_18490.htm Accessed 28th November 2008.
Nye, D., & Wasserman, N. (1999). Patterns of VC evolution: Comparing the Israeli and Indian venture capital industries. Journal of Private Equity, 3(1), 26–48.
Onis, Z. (1991). The logic of the developmental state. Comparative Politics, 24(1), 109–26.
Oster, S. (2001). Nothing ventured. AsiaWeek.com (July 27–August 3). Quoted in Kenney 2002: 107.
Parry, B. C. (2005). Trading the genome: Investigating the commodification of bio-information. New York: Columbia University Press.
Perkins, D. H. (2000). Law, family ties and the East Asian way of business. In L. Harrison & S. Huntington (Eds.), Culture matters: How values shape human progress (pp. 232–243). New York: Basic Books.
Perrin, N. (2005). The global commercialisation of stem cell research. London, UK Trade and Investment. Available at: http://www.chrismason.com/industry_library/assets/UKTI%20Stem%20Cell%20Res.pdf Accessed 15th October 2008.
Petryna, A. (2006). (2006). Globalizing Human Subjects Research. In A. Petryna, A. Lakoff & A. Kleinman (Eds.), Global pharmaceuticals: Ethics, markets, practices (pp. 33–60). Durham: Duke University Press.
Prescott, C. (2005). Investing in stem cells: a venture capital perspective. Avlar Bioventures. Presentation to the East of England Stem Cell Network, 8th March 2005. Cambridge.
Pye, L. C. (2000). Asian values: From dynamos to dominoes. In L. Harrison & S. Huntington (Eds.), Culture matters: How values shape human progress (pp. 244–255). New York: Basic Books.
Rothman, H., & Kraft, A. (2006). Downstream and into deep biology: Evolving business models in ‘top tier’ genomics companies. Journal of Commercial Biotechnology, 12(2), 86–98.
Sapienza, H. J., Manigart, S., & Vermeir, W. (1996). Venture capital governance and value added in four countries. Journal of Business Venturing, 11, 439–469.
Wade, R. (1996). National diversity and global capitalism. Cornell: Cornell University Press.
Waldby, C., & Mitchell, R. (2006). Tissue Economies: Gifts, Commodities, and Biovalue in Late Capitalism. Durham: Duke University Press.
Weiss, L. (1998). The myth of the powerless state. Cornell: Cornell University Press.
Weiss, L. (2000). Developmental states in transition: Adapting, dismantling, innovating, not ‘normalising’. The Pacific Review, 13(1), 21–55. 29.
White, S., Gao, J., & Zhang, W. (2005). Financing new venture in China: System antecedents and institutionalisation. Research Policy, 34(6), 894–913.
Wong, J. (2005). Remaking the developmental state in Taiwan: The challenges of biotechnology. International Political Science Review, 26, 169–190.
Wong, J. (2006). Technovation in Taiwan: Implications for industrial governance. Governance, 19(4), 651–72.
Wright, M., Sarika, P., & Lockett, A. (2005). International venture capital research: From cross-country comparisons to crossing borders. International Journal of Management Reviews, 7(3), 135–65.
Wu, Y. (2004). Rethinking the Taiwanese developmental state. The China Quarterly, 177, 91–114.
Zero2IPO Research Centre. (2008a). China venture capital annual report 2007. Beijing: Zero2IPO Research Centre.
Zero2IPO Research Centre. (2008b). China Venture Capital Report Q2 2008. Beijing: Zero2IPO Research Centre.
Zhang, M. (2008a). How do oversea PEs evade control by Chinese government: case analysis. Quoted by Zero2IPO Research Centre (2008b). China Venture Capital Report Q2 2008. Beijing: Zero2IPO Research Centre: 193.
Zhang, T. (2008b). Made in China? Nature, 455(7217), 1168–70.
Zhenzhen, L., Jiuchun, Z., & Ke, W. (2004). Health biotechnology in China: Reawakening of a giant. Nature Biotechnology, 22(Supplement), DC15.
Zimbio. (2009). China tops South Asia VC investments in 2008. Zimbio. Available at: http://www.zimbio.com/Venture+Capital/articles/83/China+Tops+South+Asia+VC+Investments+2008 Accessed 23 June 2009.